低氧引发的超分子自由基诱导细胞内聚合,用于精确的瘤治疗
Mian Tang1, Zhiqing Yang1, Xingchen Tang2
1State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, and MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macau SAR 999078, China.
Journal of the American Chemical Society
|January 13, 2025
概括
这项研究引入了一种新的现场聚合治疗癌症. 一个超分子系统在瘤细胞内产生自由基, 破坏瘤细胞并提供向的抗瘤治疗,
科学领域:
- 生物医学工程
- 材料科学
- 癌症学
背景情况:
- 控制释放系统的抗瘤疗法往往导致非目标副作用.
- 使用生物相容材料的现场治疗合成是一种更安全的替代方案.
研究的目的:
- 为细胞内聚合和向癌症治疗开发低氧启动的超分子自由基系统.
- 通过现场聚合来研究4T1细胞的破坏.
主要方法:
- 使用了2:1的超分子宿主-客体复合体,其中包括甲 (CB) [7]和二胺衍生物 (PDI) (PDI+2CB[7]).
- 利用瘤的低氧和减少环境产生自由基离子.
- 使用 PDI+2CB [7] 复合物在 4T1 细胞内启动 2-乙基甲酸盐 (HEMA) 的自由基聚合.
主要成果:
- PDI+2CB[7] 复合物在4T1细胞内产生了稳定的自由基离子.
- 在现场聚合破坏了4T1细胞的细胞骨架和器官.
- 实现显著的瘤代谢干扰和强烈的抗瘤反应,没有全身毒性.
结论:
- 稳定,内源性刺激诱导的超分子自由基可以触发细胞内聚合.
- 这种方法提供了选择性和有效的抗瘤治疗,而不需要常规化疗剂.
- 证明了一种更安全,更精确的癌症治疗策略.
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Electron Transport Chain: Complex I and II
10.9K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
10.9K
Radical Chain-Growth Polymerization: Overview
2.4K
Chain-growth or addition polymerization is successive addition reactions of monomers with a polymer chain. In radical chain-growth polymerization, the reaction proceeds via a free-radical intermediate. The free radical is formed from radical initiators, which spontaneously generate free radicals by homolytic fission. Organic peroxides (such as dibenzoyl peroxide, as shown in Figure 1) or azo compounds are popular radical initiators. A low concentration ratio of radical initiator to monomer is...
2.4K


